Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;29(6):557-562.
doi: 10.1177/0956462417743158. Epub 2017 Nov 29.

Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County

Matthew R Beymer  1   2 , Ryan M Kofron  3 , Chi-Hong Tseng  4 , Robert K Bolan  1 , Risa P Flynn  1 , Jennifer M Sayles  3 , Mario J Perez  5 , Wilbert C Jordan  6 , Raphael J Landovitz  2   3
Affiliations

Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County

Matthew R Beymer et al. Int J STD AIDS. 2018 May.

Abstract

Post-exposure prophylaxis (PEP) is a promising but under-utilized strategy for HIV prevention in high-risk populations. Between March 2010 and June 2011, two community-based clinics in Los Angeles County provided PEP in a pilot program to 267 unique individuals. Courses were primarily dispensed to men who have sex with men (84%) and consisted overwhelmingly of a three-drug antiretroviral therapy regimen containing two nucleoside reverse transcriptase inhibitors and either an integrase inhibitor (raltegravir) or a boosted protease inhibitor (lopinavir/ritonavir). Approximately 64% of all PEP courses were followed for at least 12 weeks, and seven individuals seroconverted. Of the seven seroconversions, six had subsequent re-exposure. The low rate of PEP failure calls for expanded funding for PEP in other jurisdictions.

Keywords: Antiretroviral therapy; HIV; North America; high-risk behavior; homosexual.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

    1. Centers for Disease Control and Prevention. Announcement: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016. 2016 [updated May. 2016/05/06:[458]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27149423. - PubMed
    1. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. PREVENTION OF SIV INFECTION IN MACAQUES BY (R)-9-(2-PHOSPHONYLMETHOXYPROPYL)ADENINE. Science. 1995;270(5239):1197–9. - PubMed
    1. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2) Journal of Virology. 2000;74(20):9771–5. - PMC - PubMed
    1. Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. Journal of Infectious Diseases. 2006;194(7):904–11. - PubMed
    1. Bourry O, Brochard P, Souquiere S, Makuwa M, Calvo J, Dereudre-Bosquet N, et al. Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. Aids. 2009;23(4):447–54. - PubMed

Publication types

MeSH terms

LinkOut - more resources